A proprietary, platform-agnostic technology for creating antibody-drug conjugates. It is designed to enhance the effective density of antigens on tumor cells, thereby improving the efficacy of ADCs, especially against tumors that express low levels of the target antigen. The platform's design also allows for multiple mechanisms of tumor cell killing.